CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Key market opportunities in the global competent cells market include rising demands in genetic engineering and synthetic ...

Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...

Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

AI-Focused Genomics Company Advancing De-Aging Science Collaborates with Leading iPS Cell Manufacturing and Research ...

Scientists first read the human genome, a three-billion-letter biological book, in April 2003. Since then, researchers have steadily advanced the ability to write DNA, moving far beyond single-gene ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world applications in medicine and agriculture.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

SHERLOCK, a rapid CRISPR-based diagnostic, detects Candida auris and antifungal resistance mutations in patient samples in under an hour.